78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details
臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05509894 (ClinicalTrials.gov) | November 2023 | 19/8/2022 | Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone | Post Marketing Surveillance (PMS) Study for Ngenla® Pre-filled Pen in Pediatric Patients Who Have Growth Disturbance Due to Insufficient Secretion of Growth Hormone in Korea | Pediatric Growth Hormone Deficiency | Drug: Ngenla | Pfizer | NULL | Not yet recruiting | 3 Years | 19 Years | All | 565 | NULL | |
| 2 | NCT05602766 (ClinicalTrials.gov) | February 6, 2023 | 27/10/2022 | Ngenla Subcutaneous Injection Special Investigation | Ngenla® Subcutaneous Injection Special Investigation | Growth Hormone Deficiency Without Epiphyseal Closure | Drug: NGENLA (Somatrogon) | Pfizer | NULL | Recruiting | N/A | 15 Years | All | 229 | Japan |